SCHEMBL5883987

SCHEMBL5883987

OCCCCCC=C1CCCC1

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
ABCB1 P08183 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18626133 1.00 DPP7 (0.31) DPP7MEN1KMT2AABCB1
SCHEMBL5883471 0.98 DPP7 (0.34) DPP7MEN1KMT2AABCB1
SCHEMBL340060 0.98 DPP7 (0.34) DPP7MEN1KMT2AABCB1
SCHEMBL5883693 0.95
SCHEMBL339384 0.95 DPP7 (0.35) DPP7MEN1KMT2AABCB1
SCHEMBL25315899 0.95 DPP7 (0.35) DPP7MEN1KMT2AABCB1
SCHEMBL14861702 0.95 DPP7 (0.35) DPP7MEN1KMT2AABCB1
SCHEMBL25312712 0.95 DPP7 (0.35) DPP7MEN1KMT2AABCB1
SCHEMBL6567356 0.91 DPP7 (0.33) DPP7MEN1KMT2AABCB1
SCHEMBL25312085 0.88 DPP7 (0.36) DPP7MEN1KMT2AABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140087988-A1 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. MANE FILS (FR) 2014-03-27 US claimed
EP-2709584-A2 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. Mane Fils (FR) 2014-03-26 EP claimed
WO-2012156649-A2 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. MANE FILS (FR) 2012-11-22 WO claimed
EP-2709584-B1 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V MANE FILS (FR) 2018-06-06 EP disclosed
EP-2709584-B1 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V MANE FILS (FR) 2018-06-06 EP disclosed
US-9593294-B2 Sensory use of 6-cyclopentylidenehexane derivatives V. MANE FILS (FR) 2017-03-14 US disclosed
US-9593294-B2 Sensory use of 6-cyclopentylidenehexane derivatives V. MANE FILS (FR) 2017-03-14 US disclosed
US-9593294-B2 Sensory use of 6-cyclopentylidenehexane derivatives V. MANE FILS (FR) 2017-03-14 US disclosed
US-9593294-B2 Sensory use of 6-cyclopentylidenehexane derivatives V. MANE FILS (FR) 2017-03-14 US disclosed
CN-103747774-A Sensory use of 6-cyclopentylidenehexane derivatives MANE FILS V 2014-04-23 CN disclosed
US-20140087988-A1 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. MANE FILS (FR) 2014-03-27 US disclosed
EP-2709584-A2 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. Mane Fils (FR) 2014-03-26 EP disclosed
EP-2709584-A2 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. Mane Fils (FR) 2014-03-26 EP disclosed
WO-2012156649-A3 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. MANE FILS (FR) 2014-01-03 WO disclosed
WO-2012156649-A2 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. MANE FILS (FR) 2012-11-22 WO disclosed
WO-2012156649-A2 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. MANE FILS (FR) 2012-11-22 WO disclosed
WO-2012156649-A2 SENSORY USE OF 6-CYCLOPENTYLIDENEHEXANE DERIVATIVES V. MANE FILS (FR) 2012-11-22 WO disclosed
WO-2009136281-A1 NITRIC OXIDE DONATING PROSTAMIDES NICOX S.A. (FR) 2009-11-12 WO disclosed
US-7091357-B2 Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2006-08-15 US disclosed
US-20030225142-A1 Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225142-A1 Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies CHRNA4, CHRNA2, CHRNA5 DPP7 4496/4885MEN1 4484/4885KMT2A 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.